Poor Beta-cell Function After the Clinical Manifestation of Type 1 Diabetes in Children Initially Positive for Islet Cell Specific Autoantibodies
The prognostic significance of islet cell specific autoantibodies at the diagnosis of Type 1 (insulin‐dependent) diabetes mellitus for the persistence of residual beta‐cell function over the first 2 years of clinical disease was evaluated in a prospective population‐based study. Seven hundred and ei...
Saved in:
Published in | Diabetic medicine Vol. 14; no. 7; pp. 532 - 537 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Chichester, UK
John Wiley & Sons, Ltd
01.07.1997
Blackwell |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The prognostic significance of islet cell specific autoantibodies at the diagnosis of Type 1 (insulin‐dependent) diabetes mellitus for the persistence of residual beta‐cell function over the first 2 years of clinical disease was evaluated in a prospective population‐based study. Seven hundred and eighty probands, aged 0.8–14.9 years, were examined for islet cell antibodies (ICA) and insulin autoantibodies (IAA), while 769 probands were studied for antibodies to glutamic acid decarboxylase (GAD65A). They were subsequently observed for 2 years. Lower serum C‐peptide concentrations and higher requirement of exogenous insulin during the follow‐up period were observed in the group of probands positive for at least one of the antibodies, especially for ICA or IAA. We conclude that the residual beta‐cell function after the presentation of Type 1 diabetes is less in children initially positive for islet cell specific autoantibodies than in those testing negative at diagnosis. This might reflect possible heterogeneity in the pathogenesis of childhood diabetes. It also demonstrates that ICA and IAA negativity at the diagnosis of Type 1 diabetes is not associated with a smaller amount of functioning beta‐cell mass, but the absence of antibodies probably reflects a slower beta‐cell destructive process and a longer duration of preclinical disease. © 1997 John Wiley & Sons, Ltd. |
---|---|
Bibliography: | Finnish Cultural Foundation University of Helsinki Juvenile Diabetes Foundation, USA - No. 188517 Orion Corporation Research Foundation, Helsinki, Finland Sigrid Juselius Foundation ark:/67375/WNG-KRXT4BSV-T ArticleID:DIA403 Alma and K.A. Snellman Foundation, Oulu, Finland Novo-Nordisk A/S, Denmark National Institute of Health, USA - No. DK-37957 istex:0ADE356979C3CE5D056F05DA7C89B8A2DA0ED8E5 Association of Finnish Life Insurance Companies Kyllikki and Uolevi Lehikoinen Foundation, Helsinki, Finland Nordisk Insulin Foundation North-Savo Foundation |
ISSN: | 0742-3071 1096-9136 1464-5491 |
DOI: | 10.1002/(SICI)1096-9136(199707)14:7<532::AID-DIA403>3.0.CO;2-6 |